Ivy Altomare, M.D., is a medical oncologist and the Vice President of Clinical Research at Paradigm Health, where she serves as the clinical lead for Paradigm’s integrated and tech-enabled prospective evidence platform. She works closely with pharmaceutical sponsors and NCI-funded consortia to evaluate evidence needs and advance pragmatic trials enhanced by Paradigm’s technology. She also leads the team of clinicians supporting trial operations and collaborates with investigators at academic medical centers and community oncology practices using Paradigm’s interoperable digital tools to accelerate clinical trial efficiency.

Kaushal Amin is a visionary technology leader currently serving as the Field CTO. A firm believer in the power of technology as a force for good, Kaushal thrives on leveraging innovative solutions to create positive outcomes for businesses, employees, and customers alike. Kaushal joined KMS in 2011, drawn by the company’s agile environment, intellectual caliber, and customer-centric culture. Based in the Atlanta office, he plays a pivotal role in bridging the gap between corporate technology strategy and real-world customer implementation. With a profound background in orchestrating complex digital transformations and scaling high-performance engineering teams, he ensures that technology roadmaps translate into tangible business value. Prior to KMS, Kaushal spent over two decades leading product development engineering organizations at industry giants including IBM, Intel, LexisNexis, and McKesson, as well as several high-growth startups. His teams have been responsible for launching disruptive technologies across diverse sectors, including Healthcare, Retail, Travel, Public Safety, and Telecommunications. To maintain excellence in a high-velocity industry, Kaushal adheres to a disciplined professional philosophy: Proactive Motivation: Staying self-driven to navigate fast-paced and demanding schedules. Priority Management: Masterfully managing time and objectives rather than being reactive to them. Balanced Culture: Utilizing a great sense of humor to foster a fun, balanced, and collaborative work environment. Kaushal earned his Bachelor of Science in Electrical and Computer Engineering from the University of Michigan, where his academic research focused on Robotics. Outside of his professional life, he is a dedicated supporter of his local sports teams, frequently cheering on Atlanta United and the Atlanta Falcons.

Bill Arneson is a seasoned professional with over two and a half decades of expertise in information technology and healthcare. Currently serving as the Director of Business Operational Transformation at Moffitt Cancer Center, he oversees teams of technical professionals, implements robotic process automation, artificial intelligence, optimizes systems and workflows, and collaborates closely with executives to foster innovation. With a robust background in healthcare revenue cycle, IT, and project management, Bill has a proven record of enhancing revenue cycle efficiency, achieving substantial cost savings, and deploying streamlined systems. He holds advanced degrees, professional certifications and excels in technical management and accelerated process improvements. Bill's commitment to delivering exceptional outcomes, complemented by his strong leadership abilities, positions him as a pivotal driver of organizational growth and operational excellence. Connect with him on social media, X.com @TheTechLeader and LinkedIn at Bill Arneson.

Liz Beatty is the Co-founder and Chief Strategy at Inato, the global technology company on a mission to bring clinical research to all patients, regardless of where they live. Liz is focused on advancing Inato’s corporate strategy, including efforts to promote diverse patient representation in clinical research as well as developing partnerships and driving growth globally. Previously, Liz headed digital clinical trials at Bristol-Myers Squibb, where she held various roles across clinical operations including site management, protocol management, recruitment and retention, and most recently digital innovation. She began her career as a clinical research coordinator at the Yale Multiple Sclerosis Research Center, bringing a unique site and sponsor perspective.

Jimmy Bechtel is the Society for Clinical Research Sites' (SCRS) Vice President of Site Engagement. He brings experience from both the site and sponsor sides of the clinical research industry to his critical role with SCRS. Jimmy provided a variety of support within the site spectrum in previous positions as data specialist, patient recruiter, and operations manager. On the pharma side where he worked in innovation project management, Jimmy utilized his previous professional experience to encourage a site-centric environment and create ease for sites working with a major sponsor company. This multifaceted background allows Jimmy to bring a unique perspective to the work he does on behalf of the sites. At SCRS, Jimmy is in charge of developing and executing the company's site-facing initiatives, and works closely with key industry partners to build out various SCRS partnership programs. Additionally, Jimmy drives the implementation the Membership department’s site-focused operations as well as design and marketing.

Matt Becker is a Strategic Advisor in SAS Health Care and Life Sciences with 40+ years’ experience, including more than 13 years at SAS. He specializes in clinical trials, analytics platforms, and data strategy. He helps organizations modernize analytics, improve compliance, and accelerate insights, leading innovations like SCE, automated pipelines, generative AI, and safety dashboards to advance clinical research and patient outcomes.

Dan Boisvert is a senior biopharma leader with 20 years of experience advancing digital transformation and data innovation in clinical development. As Senior Director and Head of Data Stewardship at Biogen, he leads global efforts in data sharing, anonymization, standards, imaging, and advancing digital maturity. His work has cut clinical data access time by over 50%, earned an FDA/PhUSE Innovation Award for an AI-informed consent chatbot, and is delivering one of the industry’s first large-scale participant data return programs. Dan brings vision, pragmatism, and radical candor to optimizing clinical trials through data and AI.

Dr. Kevin Bugin is the Head of Global Regulatory Policy and Intelligence at Amgen, Inc. Prior to his current role, Kevin was the Deputy Director of Operations in the Office of New Drugs (OND) in FDA’s Center for Drug Evaluation and Research (CDER). From May 2020 through May 2021, Dr. Bugin served as the Chief of Staff for the Therapeutics Response Efforts as part of the US Government’s HHS and DOD operation formerly known as Operation Warp Speed. Dr. Bugin is adjunct faculty at the George Washington University in the Clinical Leadership Program, focusing on areas of clinical research and medicines development. Dr. Bugin joined the FDA in 2008 in the Office of Business Process Support, then joined the Division of Gastroenterology and Inborn Errors Products within OND as a Regulatory Health Project Manager in 2010, and as the Chief of Project Management from 2015 to 2017. From 2017 until 2020, he served as the Director of Special Programs and the lead of CDER’s New Drugs Regulatory Program Modernization. Prior to joining the FDA, Dr. Bugin held roles in multiple areas and phases of drug development, including discovery (molecular biology) at the Virginia Bioinformatics Institute, translational research and technology transfer at the National Institute of Health’s Office of Technology Transfer, safety and pharmacovigilance with NIH’s National Cancer Institute’s Cancer Therapy Evaluation Program, and regulatory affairs and quality assurance at Amarex Clinical Research. Kevin received a BS in Biology and Chemistry from Virginia Tech in 2005, a MS in Biotechnology from American University in 2006, and a PhD in translational health science from George Washington University in 2020, with a focus on the Science of Team Science in drug development and regulatory science teams. He is certified in US regulatory affairs (RAC) and participates in numerous policy and regulatory science initiatives to foster drug development and promote innovation in clinical research.

Nunzio Camerlingo is an Associate Director in AI/ML Quantitative and Digital Sciences at Pfizer R&D. He drives initiatives to advance digital health innovations for faster, patient-centric clinical trials, focusing on chronic disorders and older populations. His work spans the drug development continuum, using multimodal data and AI/ML for early-phase governance and clinical support, and developing digital tools for post-approval patient adherence and persistence. Nunzio earned a Ph.D. in Biomedical Engineering from the University of Padova, Italy, with a focus on physiological modeling and algorithm development for the management of diabetes.

Andrew Chen is a strategic analytics leader with over 15 years of experience spanning R&D, clinical operations, and data science. At Bayer, he leads analytics initiatives that apply predictive modeling, real-world data, and enterprise analytics platforms to improve trial feasibility, site selection, and operational oversight. Bridging clinical strategy and advanced analytics, Andrew translates complex data into actionable insights across therapeutic areas.

Krishna Cheriath serves as the Head of Digital and AI for BioPharma Services, supporting pharma services and the PPDâ„¢ clinical research businesses of Thermo Fisher Scientific, the world leader in serving science. He leverages advanced analytics and AI to enhance clinical research and patient outcomes. With leadership roles at Zoetis, Bristol Myers Squibb and prominent consulting firms like PWC and IBM, Krishna brings over 15 years of expertise in data strategy. Additionally, he is an Adjunct Faculty at Carnegie Mellon and Rutgers, contributing to the development of data-driven leadership programs.   A digital, data, and analytics evangelist, Krishna advocates for responsible and ethical innovation. His passion for positive societal change through data and digital transformation fuels his work, along with his commitment to fostering a more connected humanity. As a champion of empowered, empathetic leadership, Krishna constantly seeks new innovations and ideas to drive impactful change.

Strategic, visionary leader with an established track record of building and leading multidisciplinary, global Informatics and IS/IT teams, driving change and simplification and delivering value through innovation. Over 20 years’ experience in the biotechnology and pharmaceutical industry working in both Discovery and Development leading projects, managing complex portfolios, driving change programs, identifying opportunities for strategic initiatives, and translating scientific and medical questions into innovative solutions. Areas of particular strength include: strategy development and implementation, translational medicine, biomedical and health informatics, evidence-based decision makings, data and decision science, and "Big Data" exploitation.

Micky Cohen-Wolkowiez is Executive Director of i-Cubed, the Center for Clinical Research Innovation at the Duke Clinical Research Institute. i-Cubed partners with innovators to turn clinical research ideas into products, services, and companies. He is also the Kiser-Arena Distinguished Professor at Duke University and Founder/CEO of ExecRx, which provides fractional medical leadership to startups. Micky has over fifteen years of experience designing and conducting clinical trials across diverse populations using traditional and decentralized models. He previously served as Scientific Advisor to the FDA’s Office of Pediatric Therapeutics and has consulted for pharmaceutical companies and startups. Micky earned his medical degree at the Central University of Venezuela, completed pediatric residency at Nicklaus Children’s Hospital, fellowship in pediatric infectious diseases at Duke University, and a PhD in pharmaceutical sciences at UNC-Chapel Hill.

Vinod Das is a leading techno-functional expert with over 25+ years of experience in Pharmaceutical Research & Development IT. He is currently responsible for Artificial Intelligence enablement at Bayer Pharmaceuticals, he drives the integration of Generative AI and Language Models (LLMs) to accelerate drug discovery and clinical development. Vinod's strategic leadership in AI enablement has set new standards in pharma-tech innovation, earning him recognition as a key influencer in the industry. He actively collaborates with top academic institutions, and AI vendors to foster cutting-edge research and sustainable AI innovation. Vinod’s work bridges the gap between advanced technology and real-world applications, making him a thought leader in AI-driven healthcare outcomes.

Cris joined Sanofi Ventures in 2020 to lead investments in AI and Digital Health. He holds a 20-year track record of building startups, tech innovation platforms, and healthtech deal-making with some of the largest organizations in the world. Prior to Sanofi, Cris was a founding member of Johnson & Johnson Innovation and Global Head of Digital Innovation since 2013. He held chief digital and data responsibilities, driving digital health strategy and new venture partnerships throughout spanning the Pharmaceutical, Consumer and Medical Device businesses.? Previously, Cris led emerging technology programs within research informatics at Novartis for six years. With entrepreneurial DNA, Cris is notably known for his role in the innovation economy since co-founding Ultra Light Startups, one of the largest and oldest startup venture pitch accelerators in the U.S, catalyzing hundreds of companies in Boston, NYC, and Silicon Valley, leading to several acquisitions by major tech companies. Cris was named 40 Under 40 by the Boston Business Journal and a Top 40 Healthcare Transformer by MM&M Magazine.? Cris currently serves on the boards of Aetion, Carbon Health, Click Tx, Empatica, Medisafe, Nucleai, and Omada. Cris holds a M.Sc. in Computer Information Systems from Boston University and a B.S. in Business Administration from Suffolk University.?

Vid Desai is a nationally recognized healthcare technology leader with more than 35 years of experience transforming digital infrastructure across regulatory agencies, pharmaceutical companies, clinical research organizations, and medical device firms. As the Chief Information Officer at the U.S. Food & Drug Administration, Vid led the agency’s $1 billion digital portfolio, driving modernization across enterprise architecture, data governance, and cybersecurity. He is the founding executive of the FDA’s Office of Digital Transformation and the first CIO to serve on its Executive Committee and report directly to the FDA Commissioner. Vid brings deep expertise in translating regulatory requirements into scalable and secure operational frameworks. Prior to the FDA, he served as CIO for several private equity-backed medical device companies—including Vyaire Medical, Endochoice, and Lake Region Medical—where he led global ERP integrations, divestitures, and post-acquisition transformations across many global sites. He also held senior technology leadership roles at Quintiles (now IQVIA) and GlaxoSmithKline, spearheading infrastructure modernization and global systems strategy. With a first-class degree in Computer Science from Royal Holloway, University of London, Vid complements technical rigor with strategic foresight. His cross-sector experience enables him to advise healthcare enterprises on digital innovation, regulatory alignment, and scalable tech design. As a member of multiple advisory groups and recipient of honors including Forbes CIO Next and FedHealthIT Lifetime Achievement Awards, Vid is committed to empowering healthcare organizations to build tech ecosystems that are both resilient and mission focused.

Sina Djali has over 25 years of experience in drug and clinical development in various companies and academia. Currently he is the head of Integrated Clinical and Operations Analytics at Jansen Pharmaceuticals. In this role Sina is responsible for incorporating Risk Management principles through applied analytics in the day to day R&D clinical operations. This includes managing both data engineering and analytics/data science teams to provide sustainable solutions in support of R&D clinical operations. Prior to this role, Sina was the head of Risk Management – Central Monitoring at Janssen R&D. Previously he has been responsible for Clinical Process and System Department at Tibotec Pharmaceuticals, where he developed and implemented a data driven Quality Risk Management System. He has also held several positions in research, regulatory affairs and R&D Quality Assurance departments at Wyeth and Aventis Pharmaceuticals.

Dr. ElZarrad is the Vice President, Regulatory Policy, BridgeBio. He was the Director of the Office of Medical Policy (OMP) at FDA’s Center for Drug Evaluation and Research (CDER), where he led the development, coordination, and implementation of medical policy programs and strategic initiatives. Dr. ElZarrad currently led multiple projects focused on exploring the potential utility of real-world evidence, innovative clinical trial designs, and the integration of technological advances in pharmaceutical development. Dr. ElZarrad was the rapporteur for the International Council for Harmonisation’s ongoing work to revise the international Good Clinical Practice Guideline (ICH-E6(R2)). Prior to joining the FDA, he served as Acting Director of the Clinical and Healthcare Research Policy Division with the Office of Science Policy at the National Institutes of Health (NIH). At NIH he worked on policies related to human subject protections; the design, conduct, and oversight of clinical research; and enhancing quality assurance programs at pharmaceutical development and production facilities. He earned a doctoral degree in medical sciences with a focus on cancer metastases from the University of South Alabama, as well as a master’s degree in public health from the Johns Hopkins Bloomberg School of Public Health.

Michelle Everill is a pioneer in the field of clinical trial optimization that includes the intersection of data science, technology, innovation, and process simplification and flexibility. She has worked in clinical research since 2000 in a variety of roles at sponsors, CROs, and sites, and has participated in trials as a patient. She strives to drive more effective trials in terms of scientific advancement, patient, site, and operational burden, and the time and cost trade off. Michelle has led feasibility, data science, and business operations organizations at three of the top-ten pharma companies, consulted for and advised many organizations, and recently joined Alnylam as VP, Global Trial Optimization to further strategic approaches to innovative and curative medicines research.

Entered the industry nearly 25 years back now. Have led a wide range of technology and business organizations for 2 large pharmas throughout my career. Currently lead a team in AbbVie's Development Business Technology group with software development, data engineering, RPA and AI solutions for Clinical Development, Regulatory, Medical Affairs, Pharmacovigilance and Data Management business functions.

In her current role as Co-Founder and Senior Vice President of Strategy and Product Development at ClinEco, Inc., Marina Filshtinsky is leading platform development and working closely with an offshore team of engineers. She is also leading and coordinating the work with advisors and investors on go-to-market strategy, business model, and positioning the platform within the clinical trials industry. At her "day job" Marina is working as executive conference director for several CHI’s events including SCOPE and SCOPE Europe.

Chelsea Gallagher is the Senior Director of Drug Development Innovation and Digital Health Analytics. She is a thought leader in clinical design innovation and has spent the past few years building analytics solutions to optimize trial design for patients, investigators and sponsors, resulting in sustained tens of millions of dollars in cost avoidance per year . Her recent work has shifted focus to automation and optimized process, achieving timeline acceleration and reduced resource burden. With over ten years of experience in analytics across multiple functions, Chelsea has leveraged her expertise in design thinking, change management, and analytics techniques to solve challenging problems at BMS. She works with stakeholders to identify root cause pain points, recognize synergies across functions, and design solutions that meet future and current business needs

Experienced IT and Life Sciences leader specializing in enabling technology for pharma and biotech companies across R&D, global drug development, and clinical innovation. Known for pragmatic, big-picture thinking and hands-on leadership, I drive transformational change by applying digital solutions to enhance patient and site engagement and optimize clinical operations. Proven excellence at strategic planning, building effective teams, and delivering sustainable, high-value technology roadmaps—all with a strong passion for improving patient and sites outcomes.

Pranava leads global data science at ZS, helping pharma and biotech clients use AI and analytics to improve decision-making, enhance market access and accelerate business performance. Pranava’s areas of expertise are in analytics and helping biopharmaceutical organizations ensure their patients have access to therapies. Within analytics, Pranava has supported clients across industries on topics related to marketing, sales, product development and supply chain management leveraging advances in AI, machine learning and data science. Within value and access, Pranava has helped clients on projects spanning organization design, access and contracting strategy, evidence generation, patient services, access analytics and data strategy.

Zahiah (Zee Zee) Gueddar leverages over 17 years of diverse industry expertise encompassing delivery, finance, operational effectiveness, and the commercial sector. Zee Zee offers invaluable insight into the challenges encountered by sponsors, CRO’s, sites and patients. In her role leading IQVIA’s Financial Technology offerings, she serves as an innovative partner for clients seeking transformative outcomes and growth opportunities. Known as a strategic thinker and problem solver, Zee Zee is responsible for driving growth and differentiation, product go-to market and ensuring innovative and competitive offerings. Zee Zee is based in Southern California and is a graduate of San Diego State University.

Rodrigo Guimarães brings over 23 years of experience in the pharmaceutical and clinical research sectors, having held key roles across both sponsor organizations and CROs. Since joining IQVIA in 2006, I have served in a variety of leadership positions spanning site management, regulatory, site start-up, investigator contracts, and centralized monitoring — both at regional and global levels. Rodrigo is currently the VP, Global Head of Centralized Monitoring Services, overseeing a team of over 100 managers and a workforce exceeding 2,000 employees – executing responsibilities across Risk-Based Monitoring (RBM) implementation, go-to-market strategy, Central Monitoring delivery and Clinical Surveillance and Analytics.

Abraham founded AG Mednet in 2005 after selling his previous company to AT&T. He is a technologist with 35 years of experience in the conception, implementation and sales of advanced software systems and platforms in fields including Telecommunications and Life Sciences. He holds a B.A. in Computer Science from Cornell, and an M.S. in Computer Science (AI) from Yale.

Kristian Hammond is the Bill and Cathy Osborn Professor of Computer Science at Northwestern University and the co-founder of the Artificial Intelligence company Narrative Science (recently acquired by Salesforce). He has spent most of his career focused on the problem of making machines smarter. His research is aimed at bridging the human/machine communication gap between the data we gather and the information that is locked within it. Since the fall of 2016, he has been the faculty lead of Northwestern’s CS + X initiative, exploring how computational thinking can be used to transform fields such as the law, medicine, and education. He also directs Northwestern’s Master of Science in Artificial Intelligence (MSAI) as well as the Center for Advancing Safety of Machine Intelligence (CASMI). In January of 2023, he was named a Fellow of the Association for the Advancement of Artificial Intelligence (AAAI). He believes in humanizing computers with the aim of stopping the process of mechanizing people. Kris received his PhD from Yale.

Janie Hansen is a seasoned professional in Business Systems Transformation within Global Development Information Systems at Daiichi Sankyo, Inc. With over 20 years of experience as a business and integration architecture consultant in clinical systems, she has a proven track record of turning concepts into reality. Her expertise lies in delivering successful technology solutions and maximizing the value of technology investments in the pharmaceutical industry. Most recently, she has focused her efforts on leading transformative initiatives that leverage the potential of Generative AI.

As the former Senior Vice President and Head of Transformation at BMS, Staci was accountable to lead an integrated, enterprise focused transformation strategy and roadmap across Drug Development. This vision included a focus on adjacent partners functions to plan and deliver on our corporate pipeline and priority portfolio goals through optimization, acceleration and increased efficiency to drive delivery of our priority programs and long-term sustainability plans. Prviously, she served as Vice President, Innovative Health, Engagement, & Advocacy, at Johnson & Johnson, an appointed position, Staci was charged with creating an organizational pillar that delivers an integrated, differentiated and superior patient, site, health authority and industry leading experience for J&J’s clinical trials. With over 25 years in the biopharmaceutical sector, she is relentless in her pursuit to drive a transformational growth strategy that supports creating equal access to quality healthcare for all patients. A purpose driven leader, Staci is known for re-shaping global operations, creating an organization’s strategic vision and driving it into actionable goals, while building a more efficient and highly inclusive environment. She has an innate ability to create stability during times of uncertainty while managing conflicting priorities and multiple constituencies that lead to leadership accountability, controls and efficiencies that power enterprise value. With a proven track record in aligning cross functional leaders and capability, including quality, manufacturing, commercial, legal and regulatory, Staci successfully navigates operational complexity across often competing therapeutic areas including oncology, cardiovascular, neuroscience and immunology that leverage multiple platforms, modalities, and data science. Work experience transcends multiple industry verticals including the government, biotech, small to medium sized and big pharmaceutical companies. Active in several professional and community-based organizations, such as the National Coalition of 100 Black Women (NCBW100) and National Black MBA Association. Additionally, Staci is a founding member of Chief, the private network for executive women leaders and founded the Diversity Council at the Iona Preparatory School. She also an active member of Black Women on Boards.

Kim has 30 years of operational experience managing all phases of the drug development process. Kim is currently the Global Head of Clinical Project Operations & Dossier Delivery, the team of clinical operations leads responsible for the management of all clinical programs across the portfolio as well as the submission dossiers. Kim is a graduate of Boston University with a Bachelor’s degree in Human Physiology and a Master’s degree in Public Health. In addition to her project responsibilities, Kim is leading several projects focused around the evolving clinical trial model to build innovation and digital technology into our programs to further optimize clinical research for Sanofi and patients. In this role, Kim has led the integration of decentralized approaches into trials at Sanofi and is currently the co-lead for the IMI Trials@Home Project.

Youssef Idelcaid is Executive Director and Head of the AI Research Center at Gilead Sciences, where he leads efforts to advance artificial intelligence across global drug development functions. He contributes to Gilead’s Enterprise Data Science Council, supporting the development of AI policy, governance, and responsible adoption frameworks at scale. With nearly two decades of experience spanning biotechnology, fashion, and beauty tech at Genentech, Levi Strauss, and L’Oréal, Youssef is a trained engineer in the field of Computational and Applied Mathematics. Thought the year, Youssef's focus has been on translating cutting-edge AI research into scalable, real-world solutions that improve scientific and operational outcomes. A frequent speaker at biotech and AI conferences, he is also an active advocate for diversity in technology through the Women in Data Science community.

Focus on multimodal molecular and clinical data to inform clinical development and trial design with the emphasis on artificial intelligence and machine learning (AI/ML).

I am a data scientist with 7 years of experience developing AI solutions across diverse domains. My work spans traditional machine learning and cutting-edge large language model applications, with a focus on extracting actionable insights from complex data. I specialize in translating technical AI capabilities into practical business outcomes. Currently, I'm exploring innovative LLM use cases in the pharmaceutical industry, where natural language processing can accelerate drug discovery, enhance clinical research, and improve patient outcomes.

Sachin Karnik is a senior AI and digital transformation leader with more than two decades of experience advancing enterprise-scale innovation across life sciences, clinical development, and commercial organizations. He specializes in translating emerging technologies into practical, high-impact solutions that accelerate decision-making, streamline complex workflows, and deliver measurable business outcomes. His work emphasizes patient-centric approaches across both clinical and commercial development, ensuring technology innovation meaningfully improves experiences and outcomes. Sachin brings a pragmatic, business-first perspective grounded in real-world implementation, responsible AI adoption, and long-term value creation at scale.

McKenzie Kays is an IT Product Manager for Patient and Site Engagement within Research & Development at Bristol Myers Squibb. In her role, McKenzie leads the strategy, design, and delivery of digital products that simplify clinical trial participation and reduce operational burden for investigative sites, with a strong focus on scalable, compliant, and user-centered solutions. She has been instrumental in advancing foundational site engagement capabilities by modernizing onboarding, document exchange, and collaboration workflows across the clinical trial ecosystem. A core focus of McKenzie’s work is leveraging emerging technologies, including AI, to improve productivity, decision-making, and operational excellence. She applies agile product management practices, human-centered design, and iterative experimentation to translate complex site and patient needs into scalable digital capabilities, while continuously measuring outcomes through experience and performance metrics. Her work includes leading the development of custom digital applications that reduced document exchange burden by 30%, accelerated site activation, and delivered frictionless experiences for sites and internal teams alike.

Francis Kendall is an accomplished senior leader with extensive experience in the field of biometrics and drug development. With an MBA qualification and a people-focused leadership style, he has successfully led teams and implemented strategic change initiatives in multicultural environments. His notable roles include serving as the Head of Statistical Programming, Data and Data Sciences at Biogen, where he manages a that oversees key initiatives such as Data Stewardship, Data Science, and effective evidence delivery. Prior to that, he held positions at Astra Zeneca, Cytel, Roche, Pfizer, Novartis, Nycomed, Sandoz UK, and Hoechst UK, where he made significant contributions to statistical programming, data analysis, and strategic planning. Francis holds various qualifications, including being a Chartered Manager, Chartered Statistician, and member of professional organizations such as PHUSE and the Chartered Management Institute. He has also published articles in prestigious journals, demonstrating his expertise in artificial intelligence, machine learning, and clinical development.

Faisal M. Khan, Ph.D. is the Corporate Vice President for Artificial Intelligence and Analytics at Novo Nordisk. His team focuses on the applications of AI and data science throughout the drug development lifecycle. His interests focus on the intersections of data science, digital health, biostatistics, bioimaging, personalized medicine, and healthcare delivery. His career has encompassed all aspects of healthcare and biomedical analytics, including diagnostics, devices, clinical trials/therapeutics, and payers/insurance. Dr. Khan has worked or consulted across academia and industry with both startups and Fortune-50 companies. He has over 100 published papers, abstracts, and patents on the applications of machine learning and artificial intelligence for healthcare and the life sciences.

Salar Khan is the Regional Sales Director at AlphaLife Sciences, where he leads U.S. commercial expansion following the company’s Series A. He focuses on helping life sciences organizations accelerate regulatory and medical submissions through compliant, enterprise-grade AI solutions for CTD authoring. Prior to joining AlphaLife Sciences, Salar held multiple commercial and leadership roles at Oracle, where he led cloud technology teams across North America and was recognized with multiple performance awards. He also brings experience in AI-driven procurement platforms at Xometry, driving new business growth and mid-market expansion. Salar holds a Bachelor of Science in Biochemistry from The University of Texas at Austin, with a minor in Business Administration. With a unique blend of technical background and commercial expertise, he is passionate about advancing the adoption of AI in life sciences to improve efficiency and regulatory outcomes.

Dr. Mary Jo Lamberti manages multi-sponsored and grant-funded research projects at Tufts CSDD. She has extensive experience conducting market research on pharmaceutical industry practices and trends affecting contract research organizations and investigative sites. She has been a speaker at conferences and has published articles in trade and peer-reviewed journals. Prior to joining Tufts CSDD, Dr. Lamberti was Director of Market Research at CenterWatch. She has also worked on federally funded research studies in science education reform. Dr. Lamberti holds a B.A. from Wellesley College and a Ph.D. in Psychology from Boston University.

Priya Lobow is a senior data leader at Eli Lilly, where she serves as AVP of Data & Analytics. With expertise spanning clinical data management, data programming, and analytics, she brings both technical depth and strategic breadth to one of the most data-intensive industries in the world. Priya's defining focus is on harnessing data as a unifying force — building bridges across clinical, scientific, and operational teams so that insights move faster, decisions are better informed, and patients benefit sooner. She is deeply committed to building inclusive, future-ready data organizations that evolve alongside the rapidly changing landscape of healthcare and technology. Beyond her professional life, Priya is a writer, public speaker, and avid traveler.

Robert Loll is SVP of Business Development & Strategic Planning at Praxis, a full service patient recruitment & retention agency that specializes in optimizing study enrollment for research studies. Designing and deploying effective patient recruitment campaign strategies since 2004, Robert’s clinical background includes 15 years providing patient care for top collegiate, Olympic and disabled athletes around the world and working for outpatient rehabilitation companies including Baxter, Caremark and NovaCare.

Andrew Mackinnon is a leader at Medable spearheading the development of agentic AI tools designed to modernize clinical research. He focuses on building intelligent, autonomous systems that streamline study design, optimize trial operations, and reduce manual burden across sponsors and research sites. By integrating advanced AI capabilities into clinical trial platforms, Andrew drives innovation that improves speed, data quality, and patient access. He partners cross-functionally across product, engineering, and clinical teams to translate cutting-edge AI concepts into scalable, real-world solutions. Known for his thoughtful leadership and results-oriented approach, Andrew is committed to building scalable solutions that enable more efficient, inclusive, and data-driven clinical development.

Kwame Marfo joins Unlearn from Komodo Health, where he served as Senior Director of Product Strategy and Incubation. There, he led cross-functional teams to advance product development and drive market alignment across multiple healthcare segments, including clinical development and medical affairs. Prior to Komodo, Marfo spent more than a decade at Genentech in leadership roles across global clinical operations and manufacturing sciences and technology. As Director of Insights & Analytics for Genentech’s Global Clinical Operations, he co-founded a function that became central to trial strategy and execution, with a strong focus on improving trial representation, patient experience, and accelerating timelines. He holds a BS in Chemical Engineering from Stanford University and an MBA from the Haas School of Business at UC Berkeley.

Solution consultant with a Bachelor's in mechanical engineering. Experience in the Salesforce ecosystem and currently working in cybersecurity—specifically data encryption.

Elke S. Nelson-Nichols, Ph.D., M.B.A., is Vice President of Life Sciences Strategy at Rhino Federated Computing, where she helps biopharma organizations operationalize secure, privacy-preserving AI across the R&D lifecycle. She previously held leadership roles at Tempus AI, managing large-scale precision medicine collaborations, and at ECRI Institute, where she focused on digital transformation and medical safety. A valedictorian MBA graduate from Penn State and a Ph.D. in Molecular and Cellular Biology from the University of Iowa, Dr. Nelson-Nichols is a frequent speaker on the intersection of AI and healthcare value generation.

With a passion for people, innovation, and simplification, Samar T. Noor brings over 20 years of experience in leadership, vision, and technical knowledge. She currently holds and has held multiple roles in technical leadership, most recently heading Statistical Programming and Technologies at Bristol Myers Squibb, focusing on data, innovation, automation, and building high-performing teams. Before her current role, Samar served as Head, Data Management and Clinical Development Standards at Johnson & Johnson. While at Johnson & Johnson, Samar led organizational transformation in Data Management, Statistical Programming, and Clinical Development Standards, realizing 80% reusability of standards, increasing consistency and quality while reducing total cost of operational delivery. Samar introduced analytical innovation as a discipline and design-thinking in process improvement. Prior to the role at Johnson & Johnson, Samar worked for Novartis Pharmaceuticals, serving as Head of Data Analytics and Process Improvement in the Oncology division. In this role, she was accountable for driving the data warehousing and data analytics solutions for the Oncology division. In addition, she was accountable for business operations, process improvement, and quality across Biostatistics, Statistical Programming, and Data Management. While at Novartis, she also spearheaded the technology and processes integration workstream in the GSK Oncology acquisition. Samar holds a Bachelors and Masters degree in Computer Science from New Jersey Institute of Technology with minors in Applied Mathematics and Legal Studies. Time away from work is spent with her three daughters and her husband.

Paulius Ojeras is a clinical operations leader with 20 years of experience across biotech and CROs. He has led complex global programs in gene and cell therapy, with a strong focus on innovative trial design, outsourcing strategy, and operational execution. With deep expertise in outsourcing strategy, operational innovation, and data-driven execution, Paulius focuses on advancing trial efficacy—accelerating timelines, strengthening vendor partnerships, and integrating emerging technologies such as AI. His perspective combines hands-on operational experience with a forward-looking vision of how biotech can adapt to shifting industry dynamics and deliver transformative therapies faster.

Gian Prakash is the Director of Data and Analytics supporting Global Therapeutics at AbbVie. With a wealth of experience in data and analytics coupled with a deep understanding of the pharmaceutical industry, Gian is instrumental in shaping the vision and strategy for data-driven initiatives within the organization. In his role, Gian leads efforts to integrate data, analytics and technology into AbbVie's global therapeutic endeavors, ensuring that data is leveraged effectively to enhance decision-making and drive successful business outcomes. Under Gian's leadership, the Data and Analytics team at AbbVie thrives on a culture of collaboration and innovation, continually seeking to enhance the impact of their work across the global therapeutic landscape. His dedication to excellence ensures that AbbVie remains at the forefront of leveraging data to deliver tangible benefits to patients and the healthcare community at large.

Angela Radcliffe is a clinical research expert and data ethics evangelist with over two decades of experience driving transformation and organizational agility at the intersection of health, tech, and data. Angela’s work has impacted >100 global clinical research efforts across almost every therapeutic area. As an author and speaker, Angela uses her personal journey to demonstrate how inclusive research can impact the root causes of our most challenging social issues such as homelessness, social justice, and climate change. She is committed to delivering on the promise of digital health and decentralized clinical trials in pursuit of health equity, giving data ownership back to humans to promote authentic patient engagement and trust, the promotion of health and data literacy for all, and normalizing clinical research as a care option.

Prasanna Rao is a distinguished AI practitioner and industry thought leader, currently serving as the Chief Products and Innovation Officer at Saama Technologies. With over 30 years of experience in information technology and analytics, including more than a decade in healthcare and life sciences, Prasanna brings a wealth of knowledge and expertise to his role. Previously, as Global Head of AI/ML, Clinical Data Sciences at Pfizer Research & Development, Prasanna worked closely with stakeholders, vendors, business SMEs, machine learning developers, and data scientists to foster innovation and advance the adoption of AI in clinical data sciences. His tenure at IBM Watson as a Watson Solution Architect was marked by significant achievements in implementing AI systems for a diverse range of clients. An accomplished speaker, Prasanna regularly presents at major industry conferences, including SCDM, DIA, SCOPE, DPharm, Tufts University CSDD, and Outsourcing Clinical Trials (OCT). He is also the holder of an IBM patent titled "Monitoring Clinical Research Performance," further cementing his status as a leading authority in leveraging technology for clinical development in the pharmaceutical industry. Prasanna continues to drive transformative advancements in AI and machine learning, delivering groundbreaking solutions to accelerate clinical research and development.

Dr. Bhargava Reddy has over 21 years of experience working in the pharmaceutical industry. He is currently Head of Advanced Insights at Janssen Pharmaceutical supporting clinical operations by providing data science solutions. Prior to this role, he was Associate Director of Advanced Analytics at UCB. In this role, he was responsible for the development and application of machine learning methodologies supporting clinical decision making within Immunology and. He was also leading the analytics work supporting Risk Based Monitoring. Prior to this role, he managed a statistical programming group and was also overseeing a large statistical programming group offshore. Dr. Reddy has published several methodology papers in peer reviewed academic journals in the areas of machine learning and deep learning. He is actively involved as an associate editor for the Frontiers in AI journal and also as a reviewer on several journals. He has a Ph.D. from Oklahoma State University and MS from Northwestern University.

Dr. Jorge S. Reis-Filho leads Data Science and AI across AstraZeneca Oncology Research and Development, primarily focusing on the development and deployment of multimodal foundation models, advanced data science approaches, and agentic AI frameworks to drive innovation throughout AstraZeneca’s oncology pipeline and portfolio. Through the integration of rigorously validated AI-driven approaches across R&D, AstraZeneca aims to accelerate drug discovery and transform clinical development to advance its bold ambition in oncology: eliminating cancer as a cause of death. Dr. Reis-Filho earned a joint MD from the University of Porto, Portugal, and the Universidade Federal do Paraná, Brazil; completed histopathology training at the University of Porto; and obtained a PhD in breast cancer molecular pathology from the Institute of Cancer Research and the Royal Marsden Hospital in London, where he rose to Team Leader and subsequently Professor and Chair of Molecular Pathology. In 2012, he joined Memorial Sloan Kettering Cancer Center in New York, becoming Chief of Experimental Pathology and Director of the Experimental Pathology Fellowship Program in 2016. Author of more than 700 peer-reviewed papers, Dr. Reis-Filho has defined molecular taxonomies for rare tumours, created a predictive classification of breast cancer, elucidated the causes and consequences of intra-tumour genetic heterogeneity, and pioneered technologies ranging from single-cell DNA sequencing of archival tissue to FDA-cleared computational pathology diagnostics. His contributions to the field have been recognised by multiple awards, including the USCAP Ramzi Cotran Young Investigator Award (2010), the CRUK Future Leaders Prize (2010), the Goudie Medal and Lectureship (2023), the BCRF Larry Norton Award (2023), and the MSKCC William Gerald Award (2024). He is also the youngest individual ever elected Fellow of the Royal College of Pathologists by published works. Prior to joining AstraZeneca, Dr. Reis-Filho consulted for Goldman Sachs Merchant Banking and Bain Capital, in addition to serving on the boards of directors and scientific advisory boards for several biotechnology companies, guiding strategy across precision medicine and artificial intelligence.

Claire Riches brings over 25 years of pharma experience to help biotech teams run faster, smarter trials. At Citeline, she leads with deep expertise in clinical research, commercial strategy, and therapeutic leadership, turning complex data into clear, AI-driven clinical solutions. Claire is passionate about using data and AI to drive better decisions particularly in patient recruitment, trial diversity, and increasing the chances of success.

Arnab helps life sciences companies develop transformational data and analytics capabilities across clinical development and clinical operations analytics, real world data and insights, evidence generation, launch planning and market access analytics. He has advised pharmaceutical & medical devices companies across a diverse set of issue areas including clinical development & operations analytics strategy, driving operating model transformations, application of digital health tools and technologies in clinical development and patient & site engagement transformation for clinical trials.

Dr. Sema Sgaier is a serial entrepreneur with nearly 20 years of experience using data and behavioral science to drive innovation in healthcare. As co-founder and CEO of Surgo Health, she has led the development of the world’s most comprehensive and insightful AI-powered data platform that reveals the why behind people’s behaviors and decision-making. She previously founded Surgo Foundation and Surgo Ventures, led large-scale programs at the Gates Foundation, holds a Ph.D. in Neuroscience from New York University, and fellowship from Harvard Medical School.

Dr. Pratik Shah directs a research program advancing the integration of artificial intelligence, deep learning, and machine learning into medical diagnostics and clinical development. A professor at the University of California, he holds faculty appointments in the departments of Pathology & Laboratory Medicine, Electrical Engineering & Computer Science, and Biomedical Engineering. Dr. Shah's research integrates AI, statistics, engineering, and biomedical science to advance the diagnosis and treatment of cancer, infectious diseases, and neurological disorders. His innovations include AI-powered computational staining for cancer diagnosis, non-invasive diagnostic medical devices, and deep reinforcement learning models for optimizing drug dosages—all aimed at reducing healthcare costs and improving patient outcomes. His work focuses on real-world biological and clinical insights and cost-effective solutions to enhance accessibility, precision, and efficiency in healthcare. Dr. Shah is an expert in the clinical translation of research findings, particularly in real-world deployment platforms designed to provide equitable and affordable healthcare. Research from his lab has been published in Cell Press, Nature Digital Medicine, and Journal of the American Medical Association. A strong advocate for the ethical and regulatory advancement of AI in medicine, Dr. Shah actively contributes to discussions shaping AI policies, ensuring that healthcare AI solutions are fair, transparent, and reliable. His work has influenced industry collaborations and frameworks designed to establish responsible AI practices in clinical settings. He serves as an expert reviewer for national grant panels on emerging technologies and as an advisor on responsible AI adoption and deployment. Previously, Dr. Shah was a Principal Investigator at the Massachusetts Institute of Technology (MIT), where he led a computational medicine research program at the MIT Media Lab. He also served as the principal investigator on a memorandum of understanding with the U.S. FDA to help establish AI and machine learning research ecosystems for clinical development. Dr. Shah holds a BS, MS, and PhD in biological and data sciences and completed fellowship training at Massachusetts General Hospital, the Broad Institute of MIT and Harvard, and Harvard Medical School.

Khushboo Sharma is the CEO of Accumulus Synergy, bringing nearly two decades of leadership in regulatory innovation and policy development. She joined Accumulus in 2022 as Chief Regulatory Innovation Officer, where she led strategic efforts to modernize regulatory frameworks and foster global collaboration. Prior to Accumulus, she held key roles at BIO, the trade association and spent 11 years at the FDA, including as Deputy Director of Operations in the Office of New Drugs in CDER. Her work has shaped major regulatory initiatives, including the New Drugs Modernization effort between FDA and industry. She holds a bachelor’s degree in biotechnology and an MBA in Biotechnology and Healthcare Industry Management from Penn State University.

Hamza Sheikh is the Vice President of Business and Corporate Development at PhaseV, a Causal AI-powered technology company optimizing clinical trial design, execution, and decision-making. At PhaseV, he leads commercial growth and corporate development initiatives across biopharma, CRO, and life sciences investment firms. Prior to joining PhaseV, Hamza held business and corporate development roles at PathAI, Nimbus Therapeutics, and UroGen Pharma. Earlier in his career, he worked as a biotech investor at Syno Capital and as a consultant at EY-Parthenon, advising life sciences clients on growth strategy and transactions.

Cheyenne is a computer scientist by training and a software engineer by practice, having worked for the past ten years developing solutions for internal company usage. Cheyenne has spent the last three years at Biogen, first designing and implementing flexible and robust systems for data ingestion and now leading technical infrastructure design and implementation for the Data Science and Applied Machine Learning team with a focus on maintainability and best practices.

Dr. Laurent Spiess is Executive Director Product Solutions at Cytel with a focus on Clinical Trial design Optimization and lives in Paris, France. Laurent has been proactively engaged in promoting adoption of innovative technologies in the pharmaceutical industry. He spent more than 15 years at Cytel and helped advance the clinical trial strategies of many large, multi-national pharmaceutical companies as well as smaller biotechnology companies by assisting them in innovating and implementing adaptive clinical trial methodology into their clinical development programs. Laurent has presented at global seminars for clinical development decision makers. He chaired two innovative trial conferences and a round table aimed at defining French Adaptive Trial Guidelines. Finally, Laurent’s educational background began with a Ph.D. from Northwestern University where he studied Quantum Physics and continued on with a Post-Doctoral Fellowship at the University of Tokyo in Japan where he lived for 2 years.

Srivatsan has over thirty years of experience in growing businesses in the Digital, Data, AI, Analytics, IT, Product and Operations management areas across several industry verticals. Currently he is helping companies unlock exponential growth opportunities to scale their businesses by leveraging the power of AI. Previously as Chief Digital Officer for R&DS Technologies, IQVIA he was responsible for driving growth and leading product development and operations of R&DS Technologies. Prior to that, as Chief Growth Officer for EXL he oversaw the Sales & Marketing, Consulting and Strategy functions helping EXL become a Strategic digital transformation partner to its customers. Before that, as Venture partner, he grew Cognizant’s foray into Digital & Platforms. He identified, incubated and grew innovative digitally enabled ventures across the Healthcare & Life Sciences value chain. Early on, He was responsible for growing Cognizant’s Life Sciences business unit to be a Tier one provider. He has worked with the many of the top 50 global Life Sciences organizations providing them comprehensive end-to-end consulting, analytics, business process and IT solutions. He has provided strategic leadership in helping life sciences organizations leverage technology and the global delivery model to effectively transform their businesses. Srivatsan was recognized as the top 100 most inspiring people in the life sciences industry award by PharmaVOICE publication in 2010 and 2021. Srivatsan holds a bachelor's in electrical engineering from B.I.T.S. in India and a master's degree in electrical engineering & computer science from Northwestern University.

Sabrina Steffen is the Head of Data Sciences Innovation & Data Strategy, based in the United States. With over 20 years of experience in clinical research, Sabrina has built a distinguished career spanning data management, risk-based monitoring, data strategy, process improvement, and innovation.

As a strategic leader, she has spent the past decade driving enterprise-wide change through data and technology. Sabrina has successfully led the design and execution of large-scale transformation—embedding AI-powered, technology-enabled processes that elevate operational excellence and decision-making. She currently oversees the global data ecosystem strategy, ensuring innovation is seamlessly integrated into clinical development.

Andrew Taylor Senior Director, Clinical Data Management IQVIA Andrew has over 25 years’ experience as a Biometrics and Clinical Operations leader in the pharmaceutical industry. He has specialized in building effective organisations, from small teams to large cross-functional departments. Andrew has extensive global experience, having worked in Europe, Australia, China and the USA for large pharmaceutical companies and global CROs. Andrew joined IQVIA in July 2019 and is currently excited about the incorporation of AI-enabled processes into drug development to further improve patient outcomes. Andrew Taylor is a seasoned leader in Biometrics and Clinical Operations with 25+ years in the pharmaceutical industry. He has built regional teams and integrated them into global departments and worked in Europe, Australia, China, and the USA. At IQVIA since 2019, Andrew champions AI-driven drug development processes to improve patient outcomes.

Aman Thukral is the Head of Clinical Systems & Digital Operations at AbbVie. He has over twelve years of experience in clinical development, technology planning & business-technology alignment. In his current role, he is responsible for eCOA operations, wearables and sensors, piloting new technology initiatives. Before this position, he had worked in Deloitte, Cognizant & GlaxoSmithKline at various levels.

Milijana Ugrenovic-Petrovic, MPM, LSSGB, is the Senior Director of Clinical Research Operations at Moffitt Cancer Center. She brings 21 years of experience in clinical research, including 4 years at UF Shands, where she focused on movement disorders clinical research before transitioning into oncology operations at Moffitt. Over her 17-year tenure at Moffitt, she progressed through roles as PRMS coordinator, screening coordinator, clinical trial coordinator, and operational manager before assuming her current leadership responsibilities. She provides strategic and operational oversight for a broad portfolio of therapeutic oncology trials, including bone marrow transplant and immune cell therapies, early-phase therapeutics, immunotherapy, thoracic, hematology, gastrointestinal, and sarcoma studies. She designed and implemented Portfolio360, a data-driven dashboard integrating real-time metrics on staff effort, revenue, expenses, and patient accrual to support transparent, data-informed decision making across the clinical research enterprise. She has presented at American Association of Cancer Institutes (AACI) conferences on workload acuity, screening coordination, inpatient trial optimization, and portfolio management. In collaboration with program chairs, faculty, clinical research medical directors, and CTO leadership, she has standardized processes aligned with GCP, FDA requirements, and institutional policy while maintaining patient-centered care. She mentors emerging leaders and fosters a culture of collaborative learning. At Moffitt, she serves on the Feasibility Committee, Cancer Committee, MPACT, and the Enterprise Data Governance Committee, partnering with Data Quality, Business Intelligence, and Data Engineering teams to strengthen governance, stewardship, and security practices. At the national level, she serves as a CancerX Judge, co-chairs the AACI Clinical Research Initiative (CRI) AI Taskforce, and is an active member of the AACI Clinical Research Innovation Consortium (CRIC). She also leads Moffitt’s Clinical Research Automation and Analytics Taskforce, advancing automation and data-integration strategies that elevate clinical research operations. She holds an MPM and Lean Six Sigma Green Belt and is a member of PMI, ACHE, and ASQ.

Matt brings more than 20 years of software and leadership experience in the life sciences industry. Matt started his career as a developer and held various technical and leadership roles at Rollins Corporation, PSCI, Microsoft, Morgan Lewis, and Datalabs. In 2006, Matt co-founded NextDocs, which grew to be a global leader in clinical, quality, and regulatory document management, where he served as CTO, CSO, and Board Director for 9 years. Before joining Trialbee, Matt spent 5 years as General Manager for Life Sciences and VP Strategic Accounts for Aurea Software, which had acquired NextDocs.

Henry Wei, MD, is the Head of Development Innovation at Regeneron, focused on accelerating clinical research. Previously, he worked at Google, the White House, Aetna, and McKinsey. He has authored patents on artificial intelligence, real-world data systems, and drug safety. He completed his M.D. and Internal Medicine residency at Cornell, additional informatics training at Stanford and Harvard, and oncology integrative medicine training at Memorial Sloan Kettering Cancer Center. He earned both his graduate & undergraduate degrees at Harvard University and published research on human neuroelectrophysiology and circadian biology. Dr. Wei is adjunct faculty at Weill-Cornell Medicine in Health Policy & Research.

Dian Wessels is Director of Design at myTomorrows, where he leads product/UX design, visual design, and narrative design across patient, physician, site, and BioPharma experiences. His work focuses on making complex healthcare journeys clearer, more human, and more actionable, especially in the context of clinical trial discovery, patient recruitment, expanded access, and AI-supported decision-making.

With a background spanning visual design, education, UX, product strategy, and design leadership, Dian brings a systems-minded design lens to patient-centric healthcare innovation. At myTomorrows, he helps shape the digital journeys, content, and product experiences that connect AI-enabled matching with human patient navigation, supporting the company’s mission to make pre-approval treatment options more accessible, understandable, and actionable for patients and care teams.

Edwin A (Ed) White is the Senior Director of Data Science at Merck & Co., Inc., where he leads data science efforts in global clinical trial operations. His career has focused on delivery of business intelligence solutions in the provider, insurance, and medical device sectors before joining Merck, where he has held various roles with increasing responsibility. He holds a B.S. from the University of Delaware, an MBA and MS from Temple University, and certifications including MCITP, PMP, and ACRP-CP.

Carrie Williams brings 20 years of experience in healthcare from several vantage points within the industry. Prior to joining McKesson Ventures in 2017, Williams served as vice president of strategy and business development for digital health provider Omada Health, having held roles within McKesson’s strategy and business development team previously, working to advance strategies aimed at innovation within hospital pharmacy and clinical trial patient recruitment. She began her career in drug development, where she managed oncology clinical trials in both large pharmaceutical and biotech settings. Williams holds an MBA from the Haas School of Business at the University of California at Berkeley and an undergraduate degree in biology from the University of Massachusetts Amherst.